Orphan Disease Natural History Grants Latest FDA Incentive For Drug Development
Executive Summary
Agency will make $2m available in 2017.
You may also be interested in...
Rare Disease R&D: FDA To Use NIH Registry For Natural History Studies
NIH plans to select two dozen groups to participate in a Global Rare Disease Patient Registry pilot project, which FDA hopes will lead to a better understanding of the conditions and speed drug development.
Rare Diseases Need Ongoing Natural History Studies To Speed Trials, FDA Says
CDER Director Janet Woodcock says rare disease advocates should consider organizing patients to study a rare disease history and progression.
ANDA Submissions Drop To Start FY2021
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: